GlassScriptPhysician profile
Nicholas A Deebel
NPI 1114480456
$7,661.11
in general payments reported to CMS, 2019-2025
10 companies · $2,206 in 2025
The $2,206 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $472 · 2023: $2,952 · 2024: $1,927 · 2025: $2,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315 · Travel and Lodging: $2,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.21 |
| Travel and Lodging | $2,769.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,619.73 | 2022-2025 | Ams 700, General - Erectile Dysfunction, Ams Ambicor |
| Coloplast Corp | $1,556.19 | 2023-2025 | Titan |
| Urogen Pharma, INC. | $162.01 | 2024 | |
| Olympus America INC. | $103.68 | 2021 | |
| Endo Pharmaceuticals INC. | $76.09 | 2024 | Xiaflex |
| Endo USA, INC. | $63.44 | 2024 | Xiaflex |
| Photocure INC | $31.20 | 2025 | Cysview |
| Astrazeneca Pharmaceuticals LP | $20.78 | 2024 | Lynparza |
| Dendreon Pharmaceuticals LLC | $14.84 | 2024 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $13.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Deebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.